research 1,25-(OH)2D3 Promotes Hair Growth by Inhibiting NLRP3/IL-1β and HIF-1α/IL-1β Signaling Pathways
1,25-(OH)2D3 helps hair grow by blocking certain harmful signals.
Search
forLearn
0 / 0 results — no results
Research
5 / 1000+ results
research WNT Signaling in the Control of Hair Growth and Structure
The research shows that a gene called Wnt3 affects hair growth and structure, causing short hair and balding when overactive.
research Critical Role of ATP-P2X7 Axis in UV-Induced Melanogenesis
ATP increases melanin production in skin after UV exposure, with the P2X7 receptor being crucial for this process.
research The Multifaceted Functions of TRPV4 and Calcium Oscillations in Tissue Repair
TRPV4 helps cells repair tissue and reduce scarring by controlling calcium levels.
research The Circular RNA circNlgn Mediates Doxorubicin-Induced Cardiac Remodeling and Fibrosis
A specific RNA, circNlgn, contributes to heart damage and scarring caused by the cancer drug doxorubicin.
Community Join
5 / 79 resultscommunity Where are we on SCUBE3? Have they even started clinical trials?
The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
community Why HMI115 should work if it doesn’t affect dht?
Hair growth can be induced without stopping DHT, as seen with Minoxidil. HMI115 may work by promoting follicle growth, not targeting the root cause of hair loss (DHT).
community More great news about SCUBE3... this could be it!
SCUBE3 is a potential hair loss treatment that people are hopeful about. It may provide a solution without the side effects of finasteride.
community September 2021 update from Dr. Kang-Yell Choi [Korean "cure"]
Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.